Lexeo Therapeutics Sees Positive Results for Alzheimer's Disease Treatment

Dow Jones

30 Oct 2024

By Adriano Marchese

Lexeo Therapeutics said Wednesday that it received positive data for its Alzheimer's disease treatment, which suggests that higher doses improved results.

The clinical-stage genetic medicine company said the results are from the phase 1/2 study for its LX1001 drug.

The treatment involves around APOE genes and AD-associated tau biomarkers, two important factors in Alzheimer's disease.

"APOE2 is associated with a significantly lower risk of Alzheimer's onset and slower disease progression," the company said.

The study's primary objective was to assess safety and tolerability of the treatment. Secondary outcomes include APOE2 protein expression and changes in the biomarkers.

"The study also resulted in notable reductions in tau biomarkers, which suggest a possible effect on Alzheimer's disease pathology," said Kim Johnson, division chief for memory disorders at the neurology department at Duke University School of Medicine and a principal investigator in the study.

The data were presented at the Clinical Trials on Alzheimer's Disease conference in Madrid, Spain.

Lexeo said it contacted the Food and Drug Administration with the data it has collected. It expects to provide regulatory updates and any new development plans for the drug in 2025.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

October 30, 2024 07:26 ET (11:26 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2479031692"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2479031692\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2479031692?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-30 19:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479031692","market":"other","top_or_hot":-1,"title":"Lexeo Therapeutics Sees Positive Results for Alzheimer's Disease Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/LXEO\">Lexeo Therapeutics</a> said Wednesday that it received positive data for its Alzheimer's disease treatment, which suggests that higher doses improved results. \n</p>\n<p>\n  The clinical-stage genetic medicine company said the results are from the phase 1/2 study for its LX1001 drug. \n</p>\n<p>\n  The treatment involves around APOE genes and AD-associated tau biomarkers, two important factors in Alzheimer's disease. \n</p>\n<p>\n  \"APOE2 is associated with a significantly lower risk of Alzheimer's onset and slower disease progression,\" the company said. \n</p>\n<p>\n  The study's primary objective was to assess safety and tolerability of the treatment. Secondary outcomes include APOE2 protein expression and changes in the biomarkers. \n</p>\n<p>\n  \"The study also resulted in notable reductions in tau biomarkers, which suggest a possible effect on Alzheimer's disease pathology,\" said Kim Johnson, division chief for memory disorders at the neurology department at Duke University School of Medicine and a principal investigator in the study. \n</p>\n<p>\n  The data were presented at the Clinical Trials on Alzheimer's Disease conference in Madrid, Spain. \n</p>\n<p>\n  Lexeo said it contacted the Food and Drug Administration with the data it has collected. It expects to provide regulatory updates and any new development plans for the drug in 2025. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 30, 2024 07:26 ET (11:26 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lexeo Therapeutics Sees Positive Results for Alzheimer's Disease Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLexeo Therapeutics Sees Positive Results for Alzheimer's Disease Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-10-30 19:26</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/LXEO\">Lexeo Therapeutics</a> said Wednesday that it received positive data for its Alzheimer's disease treatment, which suggests that higher doses improved results. \n</p>\n<p>\n  The clinical-stage genetic medicine company said the results are from the phase 1/2 study for its LX1001 drug. \n</p>\n<p>\n  The treatment involves around APOE genes and AD-associated tau biomarkers, two important factors in Alzheimer's disease. \n</p>\n<p>\n  \"APOE2 is associated with a significantly lower risk of Alzheimer's onset and slower disease progression,\" the company said. \n</p>\n<p>\n  The study's primary objective was to assess safety and tolerability of the treatment. Secondary outcomes include APOE2 protein expression and changes in the biomarkers. \n</p>\n<p>\n  \"The study also resulted in notable reductions in tau biomarkers, which suggest a possible effect on Alzheimer's disease pathology,\" said Kim Johnson, division chief for memory disorders at the neurology department at Duke University School of Medicine and a principal investigator in the study. \n</p>\n<p>\n  The data were presented at the Clinical Trials on Alzheimer's Disease conference in Madrid, Spain. \n</p>\n<p>\n  Lexeo said it contacted the Food and Drug Administration with the data it has collected. It expects to provide regulatory updates and any new development plans for the drug in 2025. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 30, 2024 07:26 ET (11:26 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2479031692","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479031692","pubTimestamp":1730287560,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Lexeo Therapeutics said Wednesday that it received positive data for its Alzheimer's disease treatment, which suggests that higher doses improved results.The clinical-stage genetic medicine company said the results are from the phase 1/2 study for its LX1001 drug.The treatment involves around APOE genes and AD-associated tau biomarkers, two important factors in Alzheimer's disease.\"APOE2 is associated with a significantly lower risk of Alzheimer's onset and slower disease progression,\" the company said.The study's primary objective was to assess safety and tolerability of the treatment. Secondary outcomes include APOE2 protein expression and changes in the biomarkers.\"The study also resulted in notable reductions in tau biomarkers, which suggest a possible effect on Alzheimer's disease pathology,\" said Kim Johnson, division chief for memory disorders at the neurology department at Duke University School of Medicine and a principal investigator in the study.The data were presented at th","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LXEO":"Lexeo Therapeutics"},"translate_title":"Lexeo Therapeutics在阿尔茨海默病治疗方面取得积极成果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LXEO":1},"content_text":"By Adriano Marchese \n\n\n \n\n\nLexeo Therapeutics said Wednesday that it received positive data for its Alzheimer's disease treatment, which suggests that higher doses improved results. \n\n\n  The clinical-stage genetic medicine company said the results are from the phase 1/2 study for its LX1001 drug. \n\n\n  The treatment involves around APOE genes and AD-associated tau biomarkers, two important factors in Alzheimer's disease. \n\n\n  \"APOE2 is associated with a significantly lower risk of Alzheimer's onset and slower disease progression,\" the company said. \n\n\n  The study's primary objective was to assess safety and tolerability of the treatment. Secondary outcomes include APOE2 protein expression and changes in the biomarkers. \n\n\n  \"The study also resulted in notable reductions in tau biomarkers, which suggest a possible effect on Alzheimer's disease pathology,\" said Kim Johnson, division chief for memory disorders at the neurology department at Duke University School of Medicine and a principal investigator in the study. \n\n\n  The data were presented at the Clinical Trials on Alzheimer's Disease conference in Madrid, Spain. \n\n\n  Lexeo said it contacted the Food and Drug Administration with the data it has collected. It expects to provide regulatory updates and any new development plans for the drug in 2025. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 30, 2024 07:26 ET (11:26 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}